Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BDSI

BioDelivery Sciences International (BDSI) Stock Price, News & Analysis

BioDelivery Sciences International logo

About BioDelivery Sciences International Stock (NASDAQ:BDSI)

Advanced Chart

Key Stats

Today's Range
$5.59
$5.60
50-Day Range
$5.54
$5.60
52-Week Range
$2.50
$5.62
Volume
2.09 million shs
Average Volume
3.34 million shs
Market Capitalization
$577.05 million
P/E Ratio
6.74
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BDSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.

BDSI Stock News Headlines

Florida International University
A “starter home” for $1925?
An MIT startup just slashed the cost of producing the world’s most valuable metal — by 99%. This “miracle metal” isn’t gold, lithium, or platinum… and almost no one’s heard of it. But it could be the one material capable of saving the entire AI industry from collapse — while handing early investors a rare ground-floor opportunity.
Science
Jim Cramer's Top Stock Picks: DF MNST BDSI
See More Headlines

BDSI Stock Analysis - Frequently Asked Questions

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to analyst estimates of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioDelivery Sciences International investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), TG Therapeutics (TGTX), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/02/2021
Today
7/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:BDSI
Employees
200
Year Founded
1997

Profitability

Trailing P/E Ratio
6.74
Forward P/E Ratio
14.71
P/E Growth
N/A
Net Income
$84.86 million
Pretax Margin
17.77%

Debt

Sales & Book Value

Annual Sales
$166.70 million
Cash Flow
$0.36 per share
Price / Cash Flow
15.42
Book Value
$1.90 per share
Price / Book
2.94

Miscellaneous

Free Float
92,927,000
Market Cap
$577.05 million
Optionable
Optionable
Beta
0.56

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:BDSI) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners